XBiotech Inc. (XBIT)
NASDAQ: XBIT · Real-Time Price · USD
2.270
-0.040 (-1.73%)
Mar 6, 2026, 10:53 AM EST - Market open
Company Description
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes true human monoclonal antibodies for treating various diseases.
It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation.
The company was incorporated in 2005 and is headquartered in Austin, Texas.
XBiotech Inc.
| Country | United States |
| Founded | 2005 |
| IPO Date | Apr 15, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 88 |
| CEO | Sushma Shivaswamy |
Contact Details
Address: 5217 Winnebago Lane Austin, Texas 78744 United States | |
| Phone | 512 386 2900 |
| Website | xbiotech.com |
Stock Details
| Ticker Symbol | XBIT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001626878 |
| CUSIP Number | 98400H102 |
| ISIN Number | CA98400H1029 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sushma Shivaswamy Ph.D. | Interim Chief Executive Officer and Chief Scientific Officer |
| John Simard | Founder and Chairman |
| Angela Hu | Director of Finance |
| Dr. Qian Wu | Senior Vice President of Clinical Operations and Analytical Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 23, 2026 | SCHEDULE 13G/A | Filing |
| Jan 23, 2026 | SCHEDULE 13G/A | Filing |
| Dec 9, 2025 | 8-K | Current Report |
| Nov 12, 2025 | 10-Q | Quarterly Report |
| Oct 15, 2025 | 8-K/A | [Amend] Current report |
| Oct 3, 2025 | 8-K | Current Report |
| Sep 2, 2025 | 8-K | Current Report |
| Aug 13, 2025 | 10-Q | Quarterly Report |
| Jul 7, 2025 | ARS | Filing |
| Jul 7, 2025 | DEF 14A | Other definitive proxy statements |